PM360 Magazine’s Post

How can you ensure that drugs reach patients through the right channels at the right time? Join us on Thursday, 7th November @ 2pm AEST / 11am SGT to hear from experts from Deloitte as they share insights about the most pressing challenges facing life sciences today, and how enterprise business planning (EBP) can effectively address them. In this webinar, we will: ✅ Explore how the rise of specialty drugs, regulatory challenges, upcoming patent cliffs, new technologies, and a stricter market access environment are reshaping the life sciences landscape. ✅ Share a case study on how a global biopharmaceutical manufacturer used EBP to establish a collaborative demand and capacity planning platform, fostering seamless production planning. ✅ Give you practical guidance - a live demo, actionable steps, and critical considerations. https://lnkd.in/gij2wxad

An interesting webinar to understand impact of #inflation reduction act on Pharma industry. Do join if you are interested for market acess insight and actionable solutiona from SMEs #IRA #biopharma #lifesciences #marketacess

How does the Inflation Reduction Act (IRA) redefine compliance requirements for biopharmaceutical companies? In this Xtalks webinar, our experts Tiffany M. and Peter Yixiao Zou, Ph.D. will explore the IRA regulation changes, the scope of data requirement, and the strategic implications on drug development, pricing and market access. Register here: https://lnkd.in/gSQcFr8R #SyneosHealth

Initiating clinical studies can be challenging and even more so when you are a small or new biotech. Turn to Catalent Biologics, a trusted sterile fill/finish partner for an efficient orchestration of your project with the right scale for your Phase 1 and 2 needs. Learn more here: https://ow.ly/CXc250Sy7E8 #PharmaceuticalManufacturing #DrugDevelopment #CDMOServices #sterileinjectables https://bit.ly/4dpBTUM

How does the Inflation Reduction Act (IRA) redefine compliance requirements for biopharmaceutical companies? In this XTalks webinar, our experts Tiffany McCaslin and Peter Zou will explore the IRA regulation changes, the scope of data requirement, and the strategic implications on drug development, pricing and market access. Register here: https://ow.ly/3E5y30sFbon #SyneosHealth

How does the Inflation Reduction Act (IRA) redefine compliance requirements for biopharmaceutical companies? In this XTalks webinar, our experts Tiffany McCaslin and Peter Zou will explore the IRA regulation changes, the scope of data requirement, and the strategic implications on drug development, pricing and market access. Register here: https://ow.ly/66wY30sFcvk #SyneosHealth

How does the Inflation Reduction Act (IRA) redefine compliance requirements for biopharmaceutical companies? In this XTalks webinar, our experts Tiffany McCaslin and Peter Zou will explore the IRA regulation changes, the scope of data requirement, and the strategic implications on drug development, pricing and market access. Register here: https://ow.ly/tcPn30sFxA3 #SyneosHealth

Initiating clinical studies can be challenging and even more so when you are a small or new biotech. Turn to Catalent Biologics, a trusted sterile fill/finish partner for an efficient orchestration of your project with the right scale for your Phase 1 and 2 needs. Learn more here: https://ow.ly/CXc250Sy7E8 #PharmaceuticalManufacturing #DrugDevelopment #CDMOServices #sterileinjectables https://dy.si/eFzrM

It's officially October, and you know what that means: The CRB 2024 Life Science Horizons report is finally here! While you sip your PSL, check out all the great Life Science market insights hot off the press.

Don’t miss the Horizons: Life Sciences 2024 report! This is the fifth installment of this series that features data collected from 500 industry professionals. Download it today so you stay ahead in this rapidly evolving life sciences industry: https://hubs.la/Q02MgJD00 #LifeSciences #Biopharma #PharmaceuticalManufacturing #CRBHorizons